GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Inclusion Criteria:

1. Have histologically proven pancreatic cancer that is borderline resectable

2. No systemic therapy for pancreatic cancer

3. Age >18 years old.

4. ECOG performance status 0-1.

5. Patients must have adequate organ and marrow function defined by study-specified
laboratory tests.

6. Woman of child bearing potential must have a negative pregnancy test.

7. Must use an acceptable form of birth control while on study.

8. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Had major surgery within the last 28 days

2. Had an investigational drug or device within the past 28 days

3. Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,
anti-PD-L2, anti-CTLA4, etc)

4. Prior treatment for pancreas cancer.

5. Patient on an immunosuppressive systemic treatments, such as steroids, in the past 2
years.

6. Other cancer diagnosis requiring treatment within two years

7. History of allergic reactions related to the drugs (Nivolumab, Cyclophosphamide,
GM-hetastarch, corn, dimethyl sulfoxide, fetal bovine serum, trypsin (porcine origin),
yeast or any other component of the GVAX vaccine) in this study.

8. Patients receiving growth factors within the last 14 days.

9. Currently have or have history of certain study-specified heart, liver, kidney, lung,
neurological, psychological, immune or other medical conditions.

10. Pregnant or breastfeeding.

11. Have known history of infection with HIV, hepatitis B, or hepatitis C.

12. Unwilling or unable to follow the study schedule for any reason.